Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Forty Seven Inc (FTSV)

Forty Seven Inc (FTSV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Forty Seven Inc 1490 O`BRIEN DRIVE SUITE A MENLO PARK CA 94025 USA

www.fortyseveninc.com P: 650-352-4150

Sector:

Medical

INDUSTRY GROUPING:

Medical - Drugs

Description:

Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition of CD47 by the SIRP' receptor on macrophages. Forty Seven, Inc. is based in CA, United States.

Key Statistics

Overview:

Market Capitalization, $K 4,599,379
Shares Outstanding, K 48,156
Float, K 30,146
% Float 62.60%
% of Insider Shareholders 37.40%
% of Institutional Shareholders 71.77%

Financials:

Annual Sales, $ 15,680 K
Annual Net Income, $ -87,620 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -26,240 K

Growth:

1-Year Return 447.96%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 05/11/20
Earnings Per Share ttm -2.41
EPS Growth vs. Prev Qtr -44.74%
EPS Growth vs. Prev Year 1.79%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

FTSV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -50.38%
Return-on-Assets % -44.35%
Profit Margin % -558.80%
Debt/Equity 0.00
Price/Sales 293.21
Price/Cash Flow N/A
Price/Book 12.70
Book Value/Share 7.52
Interest Coverage 0.00
60-Month Beta 0.40
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar